title: The impact of next-generation sequencing on the DNA methylation-based translational cancer research.
abstract: Epigenetics is currently in an exponential phase of growth, constituting one of the most promising fields in science, particularly in cancer research. Impaired epigenetic processes can lead to abnormal gene activity or inactivity, causing cellular disorders that are closely associated with tumor initiation and progression. Thus, there is a pivotal role of massive sequencing techniques for epigenetics, which aim to find novel biomarkers, factors of prognosis and prediction, and targets for achieving personalized treatments. We present a brief description of the evolution of next-generation sequencing technologies and its coupling with DNA methylation analysis techniques, highlighting its future in translational medicine and presenting significant findings in several malignancies. We also expose critical topics related to the implementation of these approaches, which is expected to be affordable for most research centers in the near future.
authors.affiliation: Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Soto
authors.affiliation: Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Rodriguez-Antolin
authors.affiliation: Structural and Functional Genomics, INGEMM-IdiPAZ-CIBERER, La Paz University Hospital, Madrid, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Vallespín
authors.affiliation: Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: de Castro Carpeño
authors.affiliation: Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain. Electronic address: inma.ibanezca@salud.madrid.org.
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Ibanez de Caceres
mesh_terms: D019175:DNA Methylation; D044127:Epigenesis, Genetic; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D057170:Translational Research, Biomedical